The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Is it time for composite endpoints in MPN trials?
In this video, Ruben Mesa, MD, Levine Cancer Institute, Winston-Salem, NC, discusses the potential of using composite endpoints in clinical trials for patients with myeloproliferative neoplasms (MPNs) and suggests these endpoints are the most patient-centric way to measure a therapy’s clinical impact. However, given the heterogeneity of MPNs, he highlights the need for flexibility in which components apply to each patient, as requiring eligibility for every measure would narrow trial eligibility. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
